Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.
Identifieur interne : 001396 ( Main/Exploration ); précédent : 001395; suivant : 001397Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.
Auteurs : Charbel Skayem [France] ; Nakhle Ayoub [Liban]Source :
- The American journal of the medical sciences [ 1538-2990 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (MeSH), Carvédilol (pharmacologie), Carvédilol (usage thérapeutique), Humains (MeSH), Indice de gravité de la maladie (MeSH), Infections à coronavirus (métabolisme), Infections à coronavirus (traitement médicamenteux), Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Interleukine-6 (antagonistes et inhibiteurs), Interleukine-6 (métabolisme), Pandémies (MeSH), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (métabolisme), Pneumopathie virale (traitement médicamenteux), Transmission de maladie infectieuse (prévention et contrôle), Vasodilatateurs (pharmacologie), Vasodilatateurs (usage thérapeutique).
- MESH :
- antagonistes et inhibiteurs : Interleukine-6.
- métabolisme : Infections à coronavirus, Interleukine-6, Peptidyl-Dipeptidase A, Pneumopathie virale.
- pharmacologie : Carvédilol, Inhibiteurs de l'enzyme de conversion de l'angiotensine, Vasodilatateurs.
- prévention et contrôle : Transmission de maladie infectieuse.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Carvédilol, Inhibiteurs de l'enzyme de conversion de l'angiotensine, Vasodilatateurs.
- Betacoronavirus, Humains, Indice de gravité de la maladie, Pandémies.
English descriptors
- KwdEn :
- Angiotensin-Converting Enzyme Inhibitors (pharmacology), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Betacoronavirus (MeSH), Carvedilol (pharmacology), Carvedilol (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (metabolism), Disease Transmission, Infectious (prevention & control), Humans (MeSH), Interleukin-6 (antagonists & inhibitors), Interleukin-6 (metabolism), Pandemics (MeSH), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (drug therapy), Pneumonia, Viral (metabolism), Severity of Illness Index (MeSH), Vasodilator Agents (pharmacology), Vasodilator Agents (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : Interleukin-6.
- chemical , metabolism : Interleukin-6, Peptidyl-Dipeptidase A.
- chemical , pharmacology : Angiotensin-Converting Enzyme Inhibitors, Carvedilol, Vasodilator Agents.
- chemical , therapeutic use : Angiotensin-Converting Enzyme Inhibitors, Carvedilol, Vasodilator Agents.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Disease Transmission, Infectious.
- Betacoronavirus, Humans, Pandemics, Severity of Illness Index.
DOI: 10.1016/j.amjms.2020.05.030
PubMed: 32631576
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.</title><author><name sortKey="Skayem, Charbel" sort="Skayem, Charbel" uniqKey="Skayem C" first="Charbel" last="Skayem">Charbel Skayem</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, Faculté de Médecine, Paris; Assistance Publique des Hôpitaux de Paris (APHP), Paris; Hôpital Henri Mondor, Créteil, France. Electronic address: charbelskayem@hotmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, Faculté de Médecine, Paris; Assistance Publique des Hôpitaux de Paris (APHP), Paris; Hôpital Henri Mondor, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Ayoub, Nakhle" sort="Ayoub, Nakhle" uniqKey="Ayoub N" first="Nakhle" last="Ayoub">Nakhle Ayoub</name><affiliation wicri:level="1"><nlm:affiliation>Holy Spirit University of Kaslik, Lebanon; Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Holy Spirit University of Kaslik, Lebanon; Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos</wicri:regionArea><wicri:noRegion>Byblos</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32631576</idno><idno type="pmid">32631576</idno><idno type="doi">10.1016/j.amjms.2020.05.030</idno><idno type="wicri:Area/Main/Corpus">000A77</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A77</idno><idno type="wicri:Area/Main/Curation">000A77</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A77</idno><idno type="wicri:Area/Main/Exploration">000A77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.</title><author><name sortKey="Skayem, Charbel" sort="Skayem, Charbel" uniqKey="Skayem C" first="Charbel" last="Skayem">Charbel Skayem</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, Faculté de Médecine, Paris; Assistance Publique des Hôpitaux de Paris (APHP), Paris; Hôpital Henri Mondor, Créteil, France. Electronic address: charbelskayem@hotmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, Faculté de Médecine, Paris; Assistance Publique des Hôpitaux de Paris (APHP), Paris; Hôpital Henri Mondor, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Ayoub, Nakhle" sort="Ayoub, Nakhle" uniqKey="Ayoub N" first="Nakhle" last="Ayoub">Nakhle Ayoub</name><affiliation wicri:level="1"><nlm:affiliation>Holy Spirit University of Kaslik, Lebanon; Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Holy Spirit University of Kaslik, Lebanon; Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos</wicri:regionArea><wicri:noRegion>Byblos</wicri:noRegion></affiliation></author></analytic><series><title level="j">The American journal of the medical sciences</title><idno type="eISSN">1538-2990</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors (pharmacology)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Carvedilol (pharmacology)</term><term>Carvedilol (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (metabolism)</term><term>Disease Transmission, Infectious (prevention & control)</term><term>Humans (MeSH)</term><term>Interleukin-6 (antagonists & inhibitors)</term><term>Interleukin-6 (metabolism)</term><term>Pandemics (MeSH)</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (metabolism)</term><term>Severity of Illness Index (MeSH)</term><term>Vasodilator Agents (pharmacology)</term><term>Vasodilator Agents (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term><term>Carvédilol (pharmacologie)</term><term>Carvédilol (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (métabolisme)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term><term>Interleukine-6 (antagonistes et inhibiteurs)</term><term>Interleukine-6 (métabolisme)</term><term>Pandémies (MeSH)</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Pneumopathie virale (métabolisme)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Transmission de maladie infectieuse (prévention et contrôle)</term><term>Vasodilatateurs (pharmacologie)</term><term>Vasodilatateurs (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-6</term><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Carvedilol</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Carvedilol</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Interleukine-6</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Interleukine-6</term><term>Peptidyl-Dipeptidase A</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Carvédilol</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Vasodilatateurs</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Transmission, Infectious</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Transmission de maladie infectieuse</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Carvédilol</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Vasodilatateurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Humans</term><term>Pandemics</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32631576</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>360</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>The American journal of the medical sciences</Title><ISOAbbreviation>Am. J. Med. Sci.</ISOAbbreviation></Journal><ArticleTitle>Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.</ArticleTitle><Pagination><MedlinePgn>300</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0002-9629(20)30204-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjms.2020.05.030</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skayem</LastName><ForeName>Charbel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Université de Paris, Faculté de Médecine, Paris; Assistance Publique des Hôpitaux de Paris (APHP), Paris; Hôpital Henri Mondor, Créteil, France. Electronic address: charbelskayem@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoub</LastName><ForeName>Nakhle</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Holy Spirit University of Kaslik, Lebanon; Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Sci</MedlineTA><NlmUniqueID>0370506</NlmUniqueID><ISSNLinking>0002-9629</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0K47UL67F2</RegistryNumber><NameOfSubstance UI="D000077261">Carvedilol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077261" MajorTopicYN="N">Carvedilol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018562" MajorTopicYN="N">Disease Transmission, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32631576</ArticleId><ArticleId IdType="pii">S0002-9629(20)30204-4</ArticleId><ArticleId IdType="doi">10.1016/j.amjms.2020.05.030</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Liban</li></country><region><li>Île-de-France</li></region><settlement><li>Créteil</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Skayem, Charbel" sort="Skayem, Charbel" uniqKey="Skayem C" first="Charbel" last="Skayem">Charbel Skayem</name></region></country><country name="Liban"><noRegion><name sortKey="Ayoub, Nakhle" sort="Ayoub, Nakhle" uniqKey="Ayoub N" first="Nakhle" last="Ayoub">Nakhle Ayoub</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001396 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001396 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32631576
|texte= Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32631576" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |